1. A method for manufacturing, by a transfer mold method, a power module equipped with a heat conductive insulating sheet in which an inorganic filler including secondary aggregated particles formed by aggregating scaly boron nitride primary particles is dispersed in a thermosetting resin,
the method comprising:
advancing curing of an uncured or semi-cured heat conductive insulating sheet during transfer molding such that a ratio of change of a curing degree of the heat conductive insulating sheet which is represented by formula (1) is equal to or greater than 30%:
Ratio of change (%) of curing degree of heat conductive insulating sheet=(B\u2212C)B\xd7100\u2003\u2003(1)
where, in formula (1), B represents a calorific value (calg), as measured with a differential scanning calorimeter, until the pre-transfer-molding uncured or semi-cured heat conductive insulating sheet is completely cured, and C represents a calorific value (calg), as measured with the differential scanning calorimeter, until the pre-transfer-molding uncured or semi-cured heat conductive insulating sheet is completely cured after heat treatment for 90 seconds at 180\xb0 C.
2. The method for manufacturing a power module according to claim 1, wherein a ratio of the secondary aggregated particles in the inorganic filler is equal to or greater than 20 vol %.
3. The method for manufacturing a power module according to claim 1, wherein a filling ratio of the inorganic filler in the heat conductive insulating sheet is from 30 vol % to 80 vol %.
4. A power module obtained by the method according to claim 1.
5. A power module obtained by a transfer mold method, wherein the power module comprising a heat conductive insulating sheet in which an inorganic filler including secondary aggregated particles formed by aggregating scaly boron nitride primary particles is dispersed in a thermosetting resin, and a specific gravity ratio of the heat conductive insulating sheet is equal to or greater than 92%.
6. A heat conductive insulating sheet which is obtained by a transfer mold method and in which an inorganic filler including secondary aggregated particles formed by aggregating scaly boron nitride primary particles is dispersed in a thermosetting resin, wherein,
the heat conductive insulating sheet is obtained by advancing curing of an uncured or semi-cured heat conductive insulating sheet during transfer molding such that a ratio of change of a curing degree of the heat conductive insulating sheet which is represented by formula (1) is equal to or greater than 30%:
Ratio of change (%) of curing degree of heat conductive insulating sheet=(B\u2212C)B\xd7100\u2003\u2003(1)
where, in formula (1), B represents a calorific value (calg), as measured with a differential scanning calorimeter, until the pre-transfer-molding uncured or semi-cured heat conductive insulating sheet is completely cured, and C represents a calorific value (calg), as measured with the differential scanning calorimeter, until the pre-transfer-molding uncured or semi-cured heat conductive insulating sheet is completely cured after heat treatment for 90 seconds at 180\xb0 C.
7. The heat conductive insulating sheet according to claim 6, wherein a temperature of an exothermic peak of the uncured or semi-cured heat conductive insulating sheet as measured with the differential scanning calorimeter is equal to or less than 200\xb0 C.
8. The heat conductive insulating sheet according to claim 6, wherein a ratio of the secondary aggregated particles in the inorganic filler is equal to or greater than 20 vol %.
9. The heat conductive insulating sheet according to claim 6, wherein a filling ratio of the inorganic filler in the heat conductive insulating sheet is from 30 vol % to 80 vol %.
10. The heat conductive insulating sheet according to claim 6, wherein the inorganic filler includes 40 vol % or more of an inorganic filler having a particle size equal to or greater than 45 \u03bcm.
11. The heat conductive insulating sheet according to claim 6, wherein a filling ratio of an inorganic filler having a particle size equal to or greater than 45 \u03bcm in the heat conductive insulating sheet is equal to or greater than 20 vol %.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. Compounds of formula I:
wherein
R1\u2550H, or C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, \u2550CHR3, \u2014C(O)OR3, \u2014C(O)R3, \u2014CH2C(O)OR3, \u2014CH2C(O)NHR3, where R3 is H or C1-C10 alkyl, cycloalkyl, or alkenyl;
R2\u2550C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;
X1\u2550NHR4, where R4 is H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R4 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R4 group further optionally containing one or more halogen atoms.
2. The compounds of claim 1, wherein R1 is C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or \u2550CH2.
3. The compounds of claim 2, wherein R1 is CH3 or \u2550CH2.
4. The compounds of claim 3, wherein the compound is selected from the group consisting of:
5. The compounds of claim 1, wherein R4 is \u2014CH2C(O)OR5 or \u2014CH2C(O)NHR5, where R5 is H, C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
6. The compounds of claim 5, wherein the compound is selected from the group consisting of:
7. Compounds of formula II:
wherein
R6\u2550H, or C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, \u2014C(O)OR8, \u2014C(O)R8, \u2014CH2C(O)OR8, \u2014CH2C(O)NHR8, where R8 is H or C1-C10 alkyl, cycloalkyl, or alkenyl;
R7\u2550C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;
X2\u2550NHR9, where R9 is H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R9 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or ah ether group, the R9 group further optionally containing one or more halogen atoms;
with the proviso that when R6 is \u2014CH3, and R7 is n-C13H27, X2 is not \u2014NHC2H5.
8. The compounds of claim 7, wherein R6 is C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
9. The compounds of claim 8, wherein R6 is \u2014CH3.
10. The compounds of claim 7, wherein R9 is \u2014CH2C(O)OR10 or \u2014CH2C(O)NHR10, where R10 is H, C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
11. Compounds of formula IV:
wherein
R16\u2550H, or C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, \u2014C(O)OR18, \u2014C(O)R18, \u2014CH2C(O)OR18, \u2014CH2C(O)NHR18, where R18 is H or C1-C10 alkyl, cycloalkyl, or alkenyl;
R17\u2550C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;
X4\u2550OR19, where R19 is C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R19 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R19 group further optionally containing one or more halogen atoms;
with the proviso that when R16 is \u2014CH3 and R19 is \u2014CH3, then R17 is not substituted or unsubstituted phenyl, -nC3H7, -nC5H11, -nC13H27,
and with the further proviso that when R16 is H and R19 is \u2014CH3, then R17 is not substituted or unsubstuted phenyl or \u2014CH3, and when R16 is H and R19 is \u2014CH2CH3, then R17 is not -iC3H7, or substituted or unsubstituted phenyl.
12. The compounds of claim 11, wherein R16 is C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
13. The compounds of claim 12, wherein R16 is \u2014CH3.
14. The compounds of claim 11, wherein R19 is \u2014CH2C(O)OR20 or \u2014CH2C(O)NHR20, where R20 is C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
15. Compounds of formula V:
wherein
R21\u2550C2-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, \u2550CHR23, \u2014C(O)OR23, \u2014C(O)R23, \u2014CH2C(O)OR23, \u2014CH2C(O)NHR23, where R23 is H or C1-C10 alkyl, cycloalkyl, or alkenyl, except when R21 is \u2550CHR23, R23 is not H;
R22\u2550C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;
with the proviso that when R21 is \u2014COOH, then R22 is not \u2014CH3, -nC5H11, or C13H27, and with the further proviso that when R21 is \u2014CH2COOH, then R22 is not \u2014CH3, \u2014CH2CH3, or -iC5H11.
16. The compounds of claim 15, wherein R21 is C2-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
17. The compounds of claim 16, wherein R21 is \u2550CH2.
18. Compounds of formula VI:
wherein:
R24\u2550C2-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, \u2014C(O)OR26, \u2014C(O)R26, \u2014CH2C(O)OR26, \u2014CH2C(O)NHR26, where R26 is H or C1-C10 alkyl, cycloalkyl, or alkenyl;
R25\u2550C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;
with the proviso that when R24 is \u2014COOH, then R25 is not \u2014CH3, -nC5H11, or C13H27, and with the further proviso that when R24 is \u2014CH2COOH, then R25 is not CH3, \u2014CH2CH3, or
19. The compounds of claim 18, wherein R21 is C2-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
20. Compounds of formula VII:
wherein R27\u2550C3-C4 alkyl, C6-C10 alkyl, C12 alkyl, C14 alkyl, C16-C20 alkyl.
21. The compounds of claim 20, selected from the group consisting of:
22. A compound of formula VIII:
wherein R28 is C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, with the proviso that R28 is not \u2014CH3, -nC3H7, -nC11H23, or -nC13H27.
23. A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IX:
R29\u2550H, or C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, \u2550CHR31, \u2014C(O)OR31, \u2014C(O)R31, \u2014CH2C(O)OR31, \u2014CH2C(O)NHR31, where R31 is H or C1-C10 alkyl, cycloalkyl, or alkenyl;
R30\u2550C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;
X5\u2550\u2014OR32, or \u2014NHR32, where R32 is H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R32 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R32 group further optionally containing one or more halogen atoms;
with the proviso that when R29 is \u2550CH2, then X5 is not OH.
24. The pharmaceutical compositions of claim 23, wherein R29 is C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or \u2550CH2.
25. The pharmaceutical compositions of claim 24, wherein R29 is \u2014CH3 or \u2550CH2.
26. The pharmaceutical compositions of claim 23, wherein R32 is \u2014CH2C(O)OR33 or \u2014CH2C(O)NH33, where R33 is C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
27. The pharmaceutical compositions of claim 23, where R29 is \u2014C6H13 or \u2014C8H17.
28. The pharmaceutical compositions of claim 23, wherein the compound is selected from the group consisting of:
29. A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 1.
30. A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 7.
31. A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 11.
32. A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 15.
33. A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 18.
34. A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 20.
35. A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 22.
36. A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to Formula III.
wherein
R11\u2550H, or C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, \u2550CHR13, \u2014C(O)OR13, \u2014C(O)R13, \u2014CH2C(O)OR13, \u2014CH2C(O)NHR13, where R13 is H or C1-C10 alkyl, cycloalkyl, or alkenyl;
R12\u2550C1-C20 alkyl cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;
X3\u2550OR14, where R14 is C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R14 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R14 group further optionally containing one or more halogen atoms.
37. The pharmaceutical formulation of claim 36, wherein R11 is C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or \u2550CH2.
38. The pharmaceutical formulation of claim 37, wherein R11 is \u2014CH3 or \u2550CH2.
39. The pharmaceutical formulation of claim 36, wherein R14 is \u2014CH2C(O)OR15 or \u2014CH2C(O)NHR15, where R15 is C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
40. A method of inducing weight loss in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
41. The method of claim 40, wherein the subject is a human.
42. The method of claim 40, wherein the subject is an animal.
43. The method of claim 41, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:
44. The method of claim 42, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:
45. A method of inhibiting growth of cancer cells in an animal or human subject, comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
46. The method of claim 45, wherein the subject is a human.
47. The method of claim 45, wherein the subject is an animal.
48. The method of claim 46, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:
49. The method of claim 47, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:
50. A method of stimulating the activity of CPT-1 in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
51. The method of claim 50, wherein the subject is a human.
52. The method of claim 50, wherein the subject is an animal.
53. The method of claim 51, wherein the compound is:
54. The method of claim 52, wherein the compound is:
55. A method of inhibiting the activity of neuropeptide-Y in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
56. The method of claim 55, wherein the subject is a human.
57. The method of claim 55, wherein the subject is an animal.
58. A method of inhibiting fatty acid synthase activity in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
59. The method of claim 58, wherein the subject is a human.
60. The method of claim 58, wherein the subject is an animal.
61. The method of claim 59, wherein the compound is selected from the group consisting of:
62. The method of claim 60, wherein the compound is selected from the group consisting of:
63. A method of inhibiting growth of invasive microbial cells in an animal or human subject comprising the administration of an effective amount of a pharmaceutical composition according to claim 23 to said subject.
64. The method of claim 63, wherein the subject is a human.
65. The method of claim 63, wherein the subject is an animal.
66. The method of claim 64, wherein the compound is selected from the group consisting of:
67. The method of claim 65, wherein the compound is selected from the group consisting of: